Engineered immune cells take aim at Hard-to-Treat lymphomas
NCT ID NCT03277729
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals are to find the safest dose and see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD20-targeted CAR T-cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could offer a new treatment option for people with B-cell lymphomas that have come back or not responded to standard therapy.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 53 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome or nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Combination therapy aims to outsmart tough lymphoma
- Targeted drug combo aims to tackle Hard-to-Treat lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers